Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9549815 | 1.00 | TBXAS1 (0.67) | TBXAS1TBXA2R | |
| SCHEMBL9549809 | 0.95 | TBXAS1 (0.60) | TBXAS1TBXA2R | |
| SCHEMBL9549576 | 0.87 | TBXAS1 (0.48) | TBXAS1 | |
| SCHEMBL9308117 | 0.86 | TBXAS1 (0.52) | TBXAS1TBXA2R | |
| Seratrodast SCHEMBL98403 | 0.86 | TBXAS1 (0.52) | TBXAS1TBXA2R | |
| Seratrodast SCHEMBL98402 | 0.86 | TBXAS1 (0.52) | TBXAS1TBXA2R | |
| SCHEMBL9308585 | 0.85 | TBXAS1 (0.50) | TBXAS1TBXA2R | |
| SCHEMBL9549644 | 0.84 | TBXAS1 (0.44) | TBXAS1 | |
| SCHEMBL3431967 | 0.83 | TBXAS1 (0.44) | TBXAS1 | |
| SCHEMBL9549745 | 0.81 | TBXAS1 (0.43) | TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0234729-B1 | QUINONE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1991-12-27 | — | — | EP | claimed |
| US-4851413-A | TREATMENT OF HEART, BRAIN, LUNG OR KIDNEY DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-07-25 | — | — | US | claimed |
| EP-0234729-A2 | Quinone derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1987-09-02 | — | — | EP | claimed |
| WO-2011146819-A2 | METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES | DMD THERAPIES, LLC (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | WHALEN ANNE | 2011-09-15 | — | — | US | disclosed |
| US-5229385-A | Thromboxane A2 and lipoxygenase inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-07-20 | — | — | US | disclosed |
| US-5106858-A | For disfunction of heart, brain, lung or kidney | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-04-21 | — | — | US | disclosed |
| EP-0234729-B1 | QUINONE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1991-12-27 | — | — | EP | disclosed |
| US-4985447-A | USEFUL FOR TREATMENT AND PREVENTION OF DISEASES DUE TO DYSFUNCTION OF HEART, BRAIN, LUNG AND KIDNEY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-01-15 | — | — | US | disclosed |
| US-4851413-A | TREATMENT OF HEART, BRAIN, LUNG OR KIDNEY DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-07-25 | — | — | US | disclosed |
| EP-0234729-A2 | Quinone derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1987-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | PYGM, TNNC1, MYOF | TBXAS1 3817/4885TBXA2R 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.